Many types of cancers, including endometrial cancer, were found to have cyclooxygenase-2 (COX-2) overexpression. Because this enzyme belongs to the group of pro-inflammatory enzymes, so-called NSAIDs (non-steroidal anti–inflammatory drugs) directly inhibit its activity. An increasing number of reports on COX-2 involvement in cancer, as well as on the role of microbiota in abnormal metabolism and signaling of cells, forces the development of new NSAID types. Besides, NSAIDs can affect some bacteria, which are vaginal/endometrial microbiome members. The overgrowth of those species was found to be a major cause of some uterus diseases. Those infections can lead to chronic inflammatory response and suppress anti-tumorigenic cell pathways. The purpose of this review is to highlight the COX-2 enzyme role in endometrial cancer, the potential effect of the endometrial microbiome on COX-2 enzyme overexpression, and the prospects of NSAIDs use in terms of this type of cancer.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are inhibitors of cyclooxygenase enzyme (COX) and were found to have positive effects in reducing the risk of developing gynecological cancers. However, long-term administration of NSAIDs carries the risk of various side effects, including those in the digestive and circulatory systems. Therefore, there is a constant need to develop new NSAID derivatives. In this work, we investigated rhenium NSAIDs, comparing their effects on endometrial cancer cells with original NSAIDs, demonstrating the high activity of aspirin and indomethacin derivatives. The cytotoxic activity of rhenium derivatives against the Ishikawa and HEC-1A cancer cell lines was higher than that of the original NSAIDs. The IC50 after 24-h incubation of Ishikawa and HEC-1A were 188.06 µM and 394.06 µM for rhenium aspirin and 228.6 µM and 1459.3 µM for rhenium indomethacin, respectively. At the same time, IC50 of aspirin and indomethacin were 10,024.42 µM and 3295.3 µM for Ishikawa, and 27,255.8 µM and 5489.3 µM for HEC-1A, respectively. Moreover, these derivatives were found to inhibit the proliferation of both cell lines in a time- and state-dependent manner. The Ishikawa cell proliferation was strongly inhibited by rhenium aspirin and rhenium indomethacin after 72-h incubation (*** = p < 0.001), while the HEC-1A proliferation was inhibited by the same agents already after 24-h incubation (*** = p < 0.001). Furthermore, the ROS level in the mitochondria of the tested cells generated in the presence of rhenium derivatives was higher than the original NSAIDs. That was associated with rhenium indomethacin exclusively, which had a significant effect (*** = p < 0.001) on both Ishikawa and HEC-1A cancer cells. Rhenium aspirin had a significant effect (*** = p < 0.001) on the mitochondrial ROS level of Ishikawa cells only. Overall, the research revealed a high potential of the rhenium derivatives of aspirin and indomethacin against endometrial cancer cells compared with the original NSAIDs.
18 September 2024 in Acta Universitatis Lodziensis. Folia Biologica et Oecologica
The human body is host to a variety of microbial species that are essential for maintaining general health. About nine percent of these microbial species inhabit the urogenital tract. It is therefore important to establish a symbiotic relationship between the host’s immune system and the microbiota in this region. Disruptions of this symbiosis can contribute to the development of pelvic inflammatory disease (PID), bacterial vaginosis (BV), vaginal candidiasis and/or even gynaecological cancers by promoting the proliferation of infectious agents. The chemotherapeutic agents currently used in cancer treatment are associated with undesirable side effects. Therefore, there is an urgent need for antitumor agents that have minimal toxicity compared to conventional treatments. Furthermore, the use of drugs to prevent or alleviate the side effects of cervical cancer treatment could significantly improve the quality of life of patients undergoing such therapy. In this review, we focus our attention on the potential efficacy of probiotics in both the prevention and therapeutic intervention of neoplasms affecting the genital tract.
18 September 2024 in Acta Universitatis Lodziensis. Folia Biologica et Oecologica
The development of next-generation sequencing (NGS) techniques allowed conducting research with greater efficiency and determining the microbial pattern of niches in the human body that were previously considered sterile. Observed changes in the microbiome composition of patients with cancer lesions increasingly indicate the role of microorganisms in the tumour induction and progression. Overgrowth of certain pathogenic strains within the tissue may cause inflammation, which in its chronic form may lead to destabilization of host genome. Such changes may result in altering the expression of genes encoding proteins involved in significant metabolic pathways and promote pathogenic cell functions such as proliferation stimulation, apoptosis inhibition and modulation of inflammatory response. Consequently, these events may lead to tissue destruction, disruption of physiological processes and development of disease states including cancer. In light of emerging reports on the role of changes in the composition of the microbiota in tumorigenesis induction and the presence of pathogenic strains in the ovarian cancer (OC) tumour microenvironment (TME), the hypothesis of a potential role for bacteria in the pathogenesis of this cancer is also gaining interest. The following review presents a summary of scientific research indicating potential role of TME bacteria in the immunopathogenesis of OC.